20

25

5

## WE CLAIM:

1. A method of treating Demyelinating Diseases said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I

$$(R)_{m} \xrightarrow{N} (R_{1})_{n}$$

$$(R_{1})_{n}$$

$$(R_{2})_{n}$$

$$(R_{1})_{n}$$

$$(R_{2})_{n}$$

$$(R_{3})_{n}$$

$$(R_{1})_{n}$$

$$(R_{2})_{n}$$

$$(R_{3})_{n}$$

$$(R_{2})_{n}$$

wherein

m is 0, 1 or 2;

n is 0, 1 or 2;

p is 0 or 1;

each R is independently hydrogen, halogen, trifluoromethyl,  $C_1$ - $C_6$ alkyl,  $C_1$ - $C_6$ alkoxy, benzyloxy, hydroxy, nitro or amino;

each R<sub>1</sub> is independently hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkenyl,

 $C_1$ - $C_6$ alkanoyl, halogen, cyano, - $C(O)C_1$ - $C_6$ alkyl, - $C_1$ - $C_6$ alkyleneCN, - $C_1$ - $C_6$ alkyleneNR'R" wherein R' and R" are each independently hydrogen or  $C_1$ -

C<sub>6</sub>alkyl,

-C<sub>1</sub>-C<sub>6</sub>alkyleneOC(O)C<sub>1</sub>-C<sub>6</sub>alkyl, or -CH(OH)R<sub>4</sub> wherein R<sub>4</sub> is hydrogen or C<sub>1</sub>-C<sub>6</sub>alkyl;

 $R_2$  is hydrogen,  $C_1$ - $C_6$ alkyl optionally substituted with halogen, hydroxy or benzyloxy,  $C_1$ - $C_6$ alkenyl,  $C_1$ - $C_6$ alkynyl,

-CO<sub>2</sub>C<sub>1</sub>-C<sub>6</sub>alkyl, or  $-R_5$ -NR' R" wherein  $R_5$  is C<sub>1</sub>-C<sub>6</sub>alkylene, C<sub>1</sub>-C<sub>6</sub>alkenylene or C<sub>1</sub>-C<sub>6</sub>alkynylene and R' and R" are each independently hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl or alternatively the group -NR'R" as a whole is 1-pyrrolidinyl; and

R<sub>3</sub> is hydrogen, nitro, amino, halogen, C<sub>1</sub>-C<sub>6</sub>alkoxy, hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl

5

or a pharmaceutically acceptable salt thereof.

- 2. The method of claim 1 wherein R is hydrogen, halogen, trifluoromethyl, or  $C_1$ - $C_6$ alkyl;  $R_1$  is hydrogen or  $C_1$ - $C_6$ alkyl;  $R_2$  is hydrogen or  $C_1$ - $C_6$ alkyl or halogen; and p is 0.
- 3. The method of claim 1 wherein the Demyelinating Disease is multiple sclerosis.
- 4. The method of claim 2 wherein the compound has the following formula

- 5. The method of claim 4 wherein the Demyelinating Disease is multiple sclerosis.
- 6. A method of treating Demyelinating Conditions said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.
- 7. The method of claim 6 wherein R is hydrogen, halogen, trifluoromethyl, or  $C_1$ - $C_6$ alkyl;  $R_1$  is hydrogen or  $C_1$ - $C_6$ alkyl;  $R_2$  is hydrogen or  $C_1$ - $C_6$ alkyl or halogen; and p is 0.
- 8. The method of claim 6 wherein the Demyelinating Condition is Spinal Cord Injury.
- 9. The method of claim 6 wherein the Demyelinating Condition is Traumatic Brain Injury.
- 10. The method of claim 6 wherein the Demyelinating Condition is Stroke.
- 11. The method of claim 7 wherein the compound has the following formula

- 12. The method of claim 11 wherein the Demyelinating Condition is Spinal Cord Injury.
- 5 13. The method of claim 11 wherein the Demyelinating Condition is Traumatic Brain Injury.
  - 14. The method of claim 11 wherein the Demyelinating Condition is Stroke.
  - 15. A method of Stroke Rehabilitation said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.
  - 16. The method of claim 14 wherein R is hydrogen, halogen, trifluoromethyl, or  $C_1$ - $C_6$ alkyl;  $R_1$  is hydrogen or  $C_1$ - $C_6$ alkyl;  $R_2$  is hydrogen or  $C_1$ - $C_6$ alkyl or halogen; and p is 0.
  - 17. The method of claim 16 wherein the compound has the following formula

20

- 18. A method of blocking the potassium channel in a patient in need thereof by administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.
- 19. The method of claim 18 wherein R is hydrogen, halogen, trifluoromethyl, or  $C_1$ - $C_6$ alkyl;  $R_1$  is hydrogen or  $C_1$ - $C_6$ alkyl;  $R_2$  is hydrogen or  $C_1$ - $C_6$ alkyl or halogen; and p is 0.
- 20. The method of claim 19 wherein the compound has the following formula

5 21. The method of claim 2 wherein the compound has the following formula

22. The method of claim 7 wherein the compound has the following formula

- 10
- 23. The method of claim 22 wherein the demyelinating condition is Spinal Cord Injury.
- 24. The method of claim 22 wherein the demyelinating condition is Traumatic Brain Injury.
  - 25. The method of claim 22 wherein the demyelinating condition is Stroke.

- 26. A method of treating Neuropathic Pain said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.
- 5 27. The method of claim 26 wherein the compound has the following formula:

- 28. A method of treating Bladder Irritation said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.
- 29. The method of claim 28 wherein the compound has the following formula:

- 30. A method of treating Over Active Bladder said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.
- 31. The method of claim 30 wherein the compound has the following formula:

- 32. A method of treating chemokine-induced pain said method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 1.
- 33. The method of claim 32 wherein the compound has the following formula: